A FOXA1/SPDEF Co-regulatory Axis Drives ERBB2 and Suppresses TEAD/YAP-Driven EMT to Maintain Luminal Identity in HER2+ Breast Cancer
Jaekwang JeongiD, Jong Won LeeiD, Seungsoo KimiD, Jaechul LimiD, Jaehun Shin, Kwangmin YooiD, Jonghun KimiD, Yoshiaki TanakaiD, Hyun Seop Tae, Lark Kyun KimiD, In‐Hyun ParkiD, Samir ZaidiiD, John J. WysolmerskiiD, Jungmin ChoiiD
Abstract
The function of the pioneer factor forkhead box A1 (FOXA1) in estrogen receptor (ER)-negative, human epidermal growth factor receptor 2 (HER2, encoded by the ERBB2 gene)-positive breast cancer represents a critical gap in our understanding of lineage identity in tumorigenesis. Here, we solve this enigma by addressing this question through the identification of an indispensable, co-dependent regulatory circuit formed between FOXA1 and the SAM pointed domain containing ETS-family transcription factor (SPDEF). Using integrative multi-omics analyses of patient tumors and experimental models, we demonstrate that this circuit functions as the master guardian of the HER2-positive luminal state. It executes this role via two distinct, essential mechanisms: it directly binds regulatory elements to drive high-level expression of the ERBB2 oncogene, and it simultaneously preserves epithelial identity by suppressing a latent program of epithelial-to-mesenchymal transition (EMT). Mechanistically, the FOXA1/SPDEF circuit promotes the expression of the transcriptional repressor TRPS1, which in turn antagonizes the pro-mesenchymal activity of the TEAD/YAP complex. Our findings define a central regulatory node that couples lineage fidelity to oncogenic output in HER2-positive cancer, revealing the FOXA1/SPDEF-TRPS1 axis as a critical determinant of tumor plasticity and a potential therapeutic target for overcoming resistance in HER2-positive breast cancer.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Breast tumors escape endocrine therapy by ER-independent mechanisms triggered by the coordinated activities of HER2/HER3 and deacetylated FOXA1
S. Gilfillan, S. Wang, … A. Hurtado-Rodriguez·bioRxiv·Sep 22, 2020
- Synergistic interplay between PHF8 and HER2 signaling contributes to breast cancer development and drug resistance
- The transcription factor AP-2β defines active enhancers conferring molecular apocrine cell identity in breast cancer
Ebtihal H Mustafa, Geraldine Laven‐Law, … Theresa E. Hickey·bioRxiv·Jul 5, 2025
- Epigenetic downregulation of HER2 during EMT leads to tumor resistance to HER2-targeted therapies in breast cancer
B. Nami, A. Ghanaeian, Z. Wang·bioRxiv·Mar 24, 2020
- Erbin interacts with NHERF1 and Ezrin to stabilize a membrane ErbB2 signaling complex in HER2-positive breast cancer
Jaekwang Jeong, Kwangmin Yoo, … John J. Wysolmerski·Breast Cancer ResearchPeer-reviewed·May 19, 2025
- ERBB2/HOXB13 co-amplification with interstitial deletion of BRCA1 defines a unique subset of breast cancers
Irene Rin Mitsiades, Maristela Lika Onozato, … Esther Rheinbay·bioRxiv·Aug 4, 2024